Emergent BioSolutions (EBS) Tops Q4 EPS by 46c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.43 +5.24%
EPS Growth %: -31.3%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -31.3%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.05, $0.46 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $194.7 million versus the consensus estimate of $243.33 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Upgrades 1&1 AG (1U1:GR) to Overweight
- JPMorgan Starts Accton Technology Corp. (2345:TT) at Overweight
- Barclays Downgrades Brown Forman (BF-B) to Equalweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
